Teva Pharmaceuticals (NASDAQ: TEVA) and its partner Sanofi (NASDAQ: SNY) have announced groundbreaking results from clinical trials of their drug, duvakitug, for ulcerative colitis and Crohn’s disease, two of the most prevalent forms of inflammatory bowel disease (IBD).
The announcement, which sent Teva’s stock soaring by 26.4% to $20.88 and Sanofi’s up 6.7% to $48.94, marks a significant milestone in IBD treatment development.
Promising trial results drive optimism
The trials revealed strong efficacy in treating both conditions. In ulcerative colitis patients, 36.2% of those receiving a low dose and 47.8% in the high-dose group achieved clinical remission compared to just 20.5% of the placebo group.
Among Crohn’s disease patients, 26.1% in the low-dose group and 47.8% in the high-dose group demonstrated endoscopic responses, compared to only 13% in the placebo group.
Sanofi’s head of research and development, Houman Ashrafian, described the results as “unprecedented.”
He highlighted duvakitug’s potential as a breakthrough treatment for IBD, saying,
If the magnitude of effect persists in the Phase 3 program, we believe we will have a differentiated medicine for patients who are in urgent need of new options.
The TL1A frontier
Duvakitug targets TL1A, a protein implicated in a variety of immunologic diseases.
While the initial focus is on gastrointestinal conditions like ulcerative colitis and Crohn’s disease, experts suggest duvakitug could eventually treat conditions such as arthritis and skin or lung diseases.
Teva CEO Richard Francis previously described duvakitug as a “multibillion-dollar blockbuster.”
The TL1A class has attracted significant interest, with companies like Merck (MRK) and Roche (RHHBY) investing billions to develop their own TL1A-targeting drugs.
Teva and Sanofi’s drug appears to outperform rivals in placebo-adjusted responses.
Evercore ISI analyst Umer Raffat noted Teva’s efficacy surpassed Merck’s by 16% to 27% and Roche’s by 18% to 23%.
Challenges and competition remain
Despite the promising results, Teva and Sanofi face a competitive landscape. Merck’s $10.8 billion acquisition of Prometheus Biosciences and Roche’s $7.1 billion deal to acquire Televant underscore the high stakes in this therapeutic area.
Piper Sandler analyst Christopher Raymond predicts that AbbVie’s (ABBV) Skyrizi and Rinvoq will continue gaining traction in the IBD space, even as TL1A therapies like duvakitug advance.
Safety profile and next steps
Duvakitug was well-tolerated in trials, with no new safety concerns reported, further boosting confidence in its potential.
Teva and Sanofi now face the critical Phase 3 trials, which will determine whether the drug can sustain its efficacy and safety profile.
The TL1A space is still in its infancy, but Teva and Sanofi’s strong trial results could position duvakitug as a frontrunner in the race to develop innovative treatments for IBD and related conditions.
Market impact and investor sentiment
Teva’s stock hit its highest level since December 2018, reflecting investor optimism.
Analysts like Raffat remain bullish, with outperform ratings citing the drug’s “best-in-class” efficacy.
With a growing portfolio in immunology and the potential to expand into other autoimmune conditions, Teva and Sanofi are poised to reshape the treatment landscape for inflammatory diseases.
The post TEVA stock soars 26%: What’s going on with Teva Pharmaceuticals? appeared first on Invezz
